On Feb. 28, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; 70 mg/mL injection), referencing Amgen’s PROLIA® and XGEVA®, respectively. These approvals make Celltrion the third company to receive FDA approval for a denosumab biosimilar, joining Samsung and Sandoz. Denosumab is a RANK…